Beam Therapeutics Inc. Common Stock (BEAM)

About BEAM

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparti…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

540

Website

beamtx.com/

Fundamentals

1-day range

$27.64$29.12

Market cap

$2.81B

P/E (trailing)

—

P/E (forward)

-6.12

EPS (trailing)

$-0.81

Dividend yield

—

Beta

2.20

Avg. volume

2.14M

Forecasts

13 analyst ratings

Beam Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• BEAM

  Beam Therapeutics Inc. Common Stock

  $29.31

  ▼ 3.84%
  Market cap $2.81BP/E —
  $16.02$38.26
• TARS

  Tarsus Pharmaceuticals Inc. Common Stock

  $71.84

  ▼ 0.12%
  Market cap $2.81BP/E —
  $48.2$85.25
• KOD

  Kodiak Sciences Inc Common Stock

  $37.77

  ▼ 3.45%
  Market cap $2.84BP/E —
  $8.29$47.84
• COAG

  Hemab Therapeutics Holdings Inc. Common Stock

  $44.77

  ▼ 9.55%
  Market cap $2.44BP/E —
  $23$55.42
• MESO

  Mesoblast Limited American Depositary Shares

  $17.42

  ▼ 4.18%
  Market cap $2.02BP/E —
  $1.88$3.31
• RLAY

  Relay Therapeutics Inc. Common Stock

  $18.78

  ▼ 3.30%
  Market cap $3.78BP/E —
  $3.5$21.27
• RXRX

  Recursion Pharmaceuticals Inc. Class A Common Stock

  $3.33

  ▼ 3.20%
  Market cap $1.69BP/E —
  $2.77$7.18

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target
  benzinga · 8/25/2026
• HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target
  Benzinga · 8/25/2026
• Tracking Cathie Wood's ARK Invest 13F Portfolio - Q2 2026 Update
  SeekingAlpha · 8/19/2026
• Prime Medicine: An Initial Prognosis
  SeekingAlpha · 8/11/2026
• Beam Therapeutics Q2 EPS $(1.18) Misses $(1.11) Estimate, Sales $490.000K Miss $16.370M Estimate
  Benzinga · 8/4/2026
• Beam Therapeutics: A Valuation With Upside Left
  SeekingAlpha · 8/3/2026

• Amy Simon · July 27, 2026 · Sale

  16.7K @ $25.74
• Amy Simon · June 30, 2026 · Sale

  373 @ $34.73
• John M. Evans · June 30, 2026 · Option Exercise

  25.0K @ $1.03
• John M. Evans · June 30, 2026 · Sale

  1.9K @ $34.84
• John M. Evans · June 30, 2026 · Sale

  23.1K @ $34.26
• John M. Evans · June 29, 2026 · Option Exercise

  6.3K @ $1.03
• John M. Evans · June 29, 2026 · Option Exercise

  18.7K @ $0.67
• John M. Evans · June 29, 2026 · Sale

  11.6K @ $35.91
• John M. Evans · June 29, 2026 · Sale

  13.4K @ $35.13
• Giuseppe Ciaramella · June 17, 2026 · Option Exercise

  29.0K @ $1.03
• Giuseppe Ciaramella · June 17, 2026 · Option Exercise

  6.5K @ $0.67
• Fishman Mark · June 3, 2026 · Grant

  19.7K
• Chirfi Guindo · June 3, 2026 · Grant

  19.7K
• Christi Shaw · June 3, 2026 · Grant

  19.7K
• Walsh Kathleen E · June 3, 2026 · Grant

  19.7K

Institutional Ownership

March 31, 2026

Total shares held

103.18M

Total value held

$2.38B

Institutional holders

245